Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma
Authors:
Open Access
- 19 January 2021
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 1862948
Abstract
Immune checkpoint inhibitors (ICIs) offer significant clinical benefits to a subset of cancer patients via the induction of a systemic T cell-mediated anti-cancer immune response. Thus, the dynamic characterization of T cell repertoires in the peripheral blood has the potential to demonstrate noninvasive predictive biomarkers for the clinical efficacy of ICIs. In this study, we collected tumor tissues and peripheral blood samples from 25 patients with advanced kidney cancer before anti-programmed cell death protein 1 (PD-1) treatment and 1, 3, and 6 months after treatment initiation. Furthermore, we applied a next-generation sequencing approach to characterize T cell receptor (TCR) alpha and beta repertoires. TCR repertoire analysis revealed that the responders to anti-PD-1 showed an expansion of certain T cell clones even in the blood, as evidenced by the significant decrease in the TCR diversity index and increase in the number of expanded TCR clonotypes 1 month after treatment. Interestingly, these expanded TCR clonotypes in the peripheral blood were significantly shared with tumor-infiltrating T cells in responders, indicating that they have many circulating T cells that may recognize cancer antigens. Expression analysis also revealed that 1 month after treatment, T cells from the peripheral blood of responders showed significantly elevated transcriptional levels of Granzyme B, Perforin, CD39, and PD-1, markers of cancer-associated antigen-specific T cells. Altogether, we propose that global TCR repertoire analysis may allow identifying early surrogate biomarkers in the peripheral blood for predicting clinical responses to anti-PD-1 monotherapy.Keywords
Funding Information
- JSPS KAKENHI (18K09133)
- Ono Pharmaceutical Co., Ltd
- Japan Society for the Promotion of Science (17H04329)
- Japan Society for the Promotion of Science (18K09133)
This publication has 36 references indexed in Scilit:
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanomaJournal for ImmunoTherapy of Cancer, 2015
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS)OncoImmunology, 2014
- Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer PatientsScience Translational Medicine, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Methods for comparing the diversity of samples of the T cell receptor repertoireJournal of Immunological Methods, 2007